Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149521 (
chronic pancreatitis
)
7,199
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Intravenous infusion of porcine
GIP
in man induces insulin release when a degree of hyperglycemia is present. This glucose-dependent insulinotropic response occurs when a dose of
GIP
is administered to obtain circulating levels of approximately 1 ng/ml, a physiologic level that can be achieved by the ingestion of glucose or corn oil or a mixed meal. Serum
GIP
was measured by radioimmunoassay, and the single antiserum used in all the described studies measures 2 immunoreactive forms of
GIP
. In patients with
chronic pancreatitis
receiving an oral glucose load or mixed liquid test meal,
GIP
levels have been shown to be exaggerated. Similar elevated responses have been observed in obese patients and in maturity onset diabetes. A reduced
GIP
response has been seen in patients with celiac disease. A physiologic role for
GIP
in the enteroinsular axis has been established. However, involvement of the hormone in pathophysiologic situations is equivocal.
...
PMID:Clinical studies with gastric inhibitory polypeptide. 51 74
The response of serum immunoreactive gastric inhibitory polypeptide (IR-GIP), gastrin (IRG) and insulin (IRI) to a mixed standard meal was measured in 15 controls, 6 patients with coeliac disease, 26 patients with
chronic pancreatitis
and partial duodenopancreatectomy (Whipple's procedure). Serum levels of IR-
GIP
, IRG and IRI were significantly reduced in patients with coeliac disease. The serum glucose increase was significantly smaller only during the first hour after the meal. Since small intestinal
GIP
- and G-cells are situated mainly in the glands of duodenal and jejunal mucosa their absolute number is not significantly reduced in coeliac disease. It is suggested that the release of IR-
GIP
and duodenal IRG is influenced by the rate of absorption of nutrients. In patients with
chronic pancreatitis
the IR-
GIP
release is significantly greater than in controls, the IRG release normal and the IRI response delayed. After Whipple's procedure the IR-
GIP
response is increased significantly while the IRG secretion is abolished. This demonstrates that the duodenum is not necessary for
GIP
release and that pancreatic and jejunal gastrin are without clinical significance.
...
PMID:Gastric inhibitory polypeptide (GIP), gastrin and insulin: response to test meal in coeliac disease and after duodeno-pancreatectomy. 95 38
Twenty-nine patients with
chronic pancreatitis
had a significantly greater IR-
GIP
response to a test meal than 15 controls. This increased response was not related to the degree of steatorrhoea or glucose intolerance. It was most marked in a group of patients with moderately impaired IRI release and medium steatorrhoea. From this is concluded that the IR-
GIP
response to a test meal is determined by at least two factors: 1. feedback control via insulin secretion, 2. assimilation of fat. In
chronic pancreatitis
endocrine insufficiency may induce an exaggerated
GIP
response and severe exocrine insufficiency may prevent fat induced
GIP
release. Gastrin is not involved in the different
GIP
response in patients with
chronic pancreatitis
.
...
PMID:Response of gastric inhibitory polypeptide (GIP) to test meal in chronic pancreatitis--relationship to endocrine and exocrine insufficiency. 100 49
A disturbed intraduodenal milieu and pancreatic scarring in advanced
chronic pancreatitis
(CP) may lead to changes of gut and pancreatic hormones. In the present study, the gastroduodenal mucosal content of several regulatory peptides was determined in 8 patients with severe calcific CP and 8 healthy volunteers. In addition, hormone release into the bloodstream was estimated after intraduodenal acid/glucose stimulation in the control subjects and 8 CP patients each with or without secondary diabetes mellitus (DM), and in 8 patients with juvenile DM, so that disturbed gut hormone release could be attributed either to CP or DM. While VIP release into the circulation was similar in all participants, mucosal levels of VIP and substance P were significantly elevated in the duodenal bulb and descending duodenum of CP patients. The somatostatin content of gastroduodenal mucosa in CP was at least as high as in normals. Gastrin was significantly more abundant only in the duodenal bulb of CP patients, while plasma gastrin was normal. Duodenal CCK concentrations tended to be elevated in the duodenal bulb, but not significantly. The release of secretin seemed to be higher in type-1 diabetics than in CP patients. The mucosal pattern of
GIP
was nearly identical in CP patients and controls. Compatible with this finding, the
GIP
release did not show any peculiarities in CP with or without DM or in DM. Basal and stimulated plasma levels of motilin were abnormally high in CP. Pancreatic polypeptide plasma levels were normal in DM, but significantly reduced in CP, especially in CP with DM. Fasting PP and stimulated pancreatic enzyme outputs were linearly related.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Chronic pancreatitis and diabetes mellitus: plasma and gastroduodenal mucosal profiles of regulatory peptides (gastrin, motilin, secretin, cholecystokinin, gastric inhibitory polypeptide, somatostatin, VIP, substance P, pancreatic polypeptide, glucagon, enteroglucagon, neurotensin). 246 85
The literature with respect to
GIP
is flooded with conflicting data especially with respect to its role in type 2 diabetes mellitus, obesity, type 1 diabetes mellitus and
chronic pancreatitis
. This review describes possible reasons for the discrepancies which include species variation of
GIP
, heterogeneity of molecules with different immunoreactivity and bioactivity, deterioration of immunoreactivity of standard and sample on prolonged storage and the effect of the preceding intake of type and quantity of food. The problems can be resolved by raising antibodies to synthetic human
GIP
and its fragments, the chemical characterization of and the raising of antibodies to immunoreactive
GIP
8000, the correct storage of samples and the standard preparation of subjects prior to experimental procedures.
...
PMID:Conflicting gastric inhibitory polypeptide data: possible causes. 847 32